Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. develops and commercializes biotechnology medicines for serious diseases across eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disease, neurological disease, hematologic conditions, infectious disease and rare disease. News about REGN commonly covers marketed products and pipeline programs such as EYLEA, EYLEA HD, Dupixent, Praluent, Libtayo, Kevzara, Otarmeni and investigational therapies developed through antibody, genetic medicine and RNA-based approaches.
Recurring company updates include financial results, FDA and European regulatory approvals, clinical trial data, label expansions, collaboration and licensing activity, product-access and pricing arrangements, share repurchase authorizations and corporate responsibility recognition. Regeneron's disclosures also frequently address its Sanofi collaboration around Dupixent and its use of proprietary technologies such as VelocImmune in drug discovery.
Regeneron (NASDAQ: REGN) will present new clinical data for EYLEA HD (aflibercept) 8 mg at the virtual Angiogenesis meeting on February 7, 2026. Presentations include final 64-week QUASAR results in retinal vein occlusion (RVO) and full primary Phase 3b ELARA data for monthly dosing.
FDA recently approved EYLEA HD for macular edema following RVO; QUASAR met its 36-week primary endpoint and offers the first every-two-month treatment option versus prior monthly dosing. ELARA supports a monthly option for patients needing more frequent treatment. Common adverse reactions (≥3%) are listed in the safety data.
Regeneron (NASDAQ: REGN) reported Q4 2025 revenues of $3.884B (up 3% YoY) and full-year 2025 revenues of $14.343B (up 1% YoY). Q4 GAAP EPS was $7.86 and non-GAAP EPS was $11.44. Key commercial drivers included strong Dupixent and EYLEA HD performance and increased Sanofi collaboration revenue.
Regeneron secured multiple regulatory approvals for EYLEA HD, Dupixent and Libtayo and filed BLAs/NDAs for programs including DB-OTO and garetosmab. The company plans substantial manufacturing and R&D investments in 2026.
Regeneron (NASDAQ: REGN) and Society for Science named the top 40 finalists for the Regeneron Science Talent Search 2026, representing 35 schools across 15 states and competing for more than $1.8 million in awards, including a $250,000 top prize. Finalists were selected from 300 scholars and more than 2,600 entrants based on original research. Finalists will compete March 5-11, 2026, with a public project exhibition on March 8 and winners announced March 10 in Washington, D.C. Regeneron noted its 10-year $100 million commitment and an expanded annual award distribution now totaling $3.1 million.
Regeneron (NASDAQ: REGN) will report fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, released before U.S. markets open.
The company will host a conference call and simultaneous webcast on January 30, 2026 at 8:30 AM Eastern Time. Investors may join the live webcast via Regeneron’s Investors and Media web page or register in advance to participate by telephone and receive dial-in details, a unique passcode, and registrant ID.
A replay and transcript will be archived on the company website for at least 30 days.
Regeneron (NASDAQ: REGN) and Sanofi announced that Japan's Ministry of Health, Labour and Welfare approved Dupixent (dupilumab) for children aged 6 to 11 years with severe or refractory bronchial asthma inadequately controlled by existing therapy, expanding prior approval for ages 12 and up.
Approval was supported by the global Phase 3 VOYAGE program and the EXCURSION extension, where Dupixent added to standard care reduced severe exacerbations 54%–65% and improved lung function 4.68%–5.32% versus placebo; a Japanese pediatric sub-study showed improved lung function at 12 weeks and low annual exacerbation rates.
Regeneron (NASDAQ: REGN) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.
The live webcast is scheduled for 2:15 p.m. Pacific Time / 5:15 p.m. Eastern Time and can be accessed from the company’s Investors & Media page at http://investor.regeneron.com/events-and-presentations. A replay and transcript will be archived on the company website for at least 30 days.
Regeneron (NASDAQ: REGN) reported encouraging Phase 1/2 LINKER-MM4 data for Lynozyfic (linvoseltamab) monotherapy in newly diagnosed multiple myeloma presented at ASH on Dec 7, 2025. Across 45 treated patients (50/100/200 mg), median time to response was 1.2 months and all dose groups achieved VGPR+ ≥70% with limited follow-up. Of 20 MRD-evaluable VGPR+ patients, 95% (19 of 20) were MRD negative at 10-5 sensitivity. Common TEAEs included CRS (all Grade 1) 44%, neutropenia any Grade 38% (Grade 3/4 33%), and infections in 84% (Grade 3 33%). No Grade 5 TEAEs or dose-limiting toxicities were reported.
The program will continue with a Phase 2 expansion and combination studies in earlier lines.
Regeneron (NASDAQ:REGN) and Tessera Therapeutics announced a global collaboration to develop TSRA-196, an investigational one-time gene editing therapy for alpha-1 antitrypsin deficiency (AATD).
Key points: Tessera will receive $150 million (cash upfront plus equity) and is eligible for $125 million in near/mid-term milestones; the companies will share development costs and future profits 50:50. Tessera expects to file an IND and CTA submissions by year-end. Preclinical data showed durable SERPINA1 editing in mice and non-human primates with high liver specificity and no off-target signal reported. The agreement is subject to customary closing conditions, including HSR antitrust clearance.
Regeneron (NASDAQ: REGN) and Sanofi announced on November 25, 2025 that the European Commission approved Dupixent (dupilumab) for moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12+ with inadequate response to H1 antihistamines who are naïve to anti-IgE therapy.
Approval is based on the LIBERTY-CUPID Phase 3 program: two pivotal trials (Study A and Study C, combined n=284) and an additional safety study (Study B, n=108) showing significant reductions in itch and hives at 24 weeks, higher rates of well-controlled disease and complete response, and a safety profile consistent with prior Dupixent indications. Approximately 270,000 EU patients may be eligible.
Regeneron (NASDAQ: REGN) announced FDA approval of EYLEA HD (aflibercept) Injection 8 mg on November 19, 2025, for treatment of macular edema following retinal vein occlusion (RVO) with dosing up to every 8 weeks after an initial monthly period.
The FDA also approved a monthly (every 4-week) dosing option across approved indications (wAMD, DME, DR, RVO). Approval for RVO was based on the Phase 3 QUASAR trial, which met its primary endpoint at 36 weeks showing non-inferior visual acuity gains versus EYLEA 2 mg dosed every 4 weeks.